Trade Benitec Biopharma Inc. - BNTC CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.1444 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 10.3278 |
| Open | 10.2778 |
| 1-Year Change | 261.53% |
| Day's Range | 10.2778 - 10.6478 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jan 21, 2025 | 10.6478 | 0.3700 | 3.60% | 10.2778 | 10.7778 | 10.2778 |
| Jan 17, 2025 | 10.2778 | -0.7000 | -6.38% | 10.9778 | 11.0578 | 10.2778 |
| Jan 16, 2025 | 11.0278 | 0.6100 | 5.86% | 10.4178 | 11.2778 | 10.2378 |
| Jan 15, 2025 | 10.6478 | 0.3400 | 3.30% | 10.3078 | 10.8378 | 9.9778 |
| Jan 14, 2025 | 10.3578 | 0.3800 | 3.81% | 9.9778 | 10.3778 | 9.9778 |
| Jan 13, 2025 | 10.3178 | -0.1600 | -1.53% | 10.4778 | 10.6078 | 10.2878 |
| Jan 10, 2025 | 10.8478 | 0.2200 | 2.07% | 10.6278 | 10.9478 | 10.3278 |
| Jan 8, 2025 | 10.8878 | -0.0900 | -0.82% | 10.9778 | 11.1978 | 10.6778 |
| Jan 7, 2025 | 11.1178 | 0.1400 | 1.28% | 10.9778 | 11.8978 | 10.7878 |
| Jan 6, 2025 | 11.4778 | -0.2000 | -1.71% | 11.6778 | 12.3878 | 11.3178 |
| Jan 3, 2025 | 12.0378 | 0.1600 | 1.35% | 11.8778 | 12.4078 | 11.3578 |
| Jan 2, 2025 | 11.9278 | -0.6400 | -5.09% | 12.5678 | 12.5678 | 11.6278 |
| Dec 31, 2024 | 12.6078 | 0.4800 | 3.96% | 12.1278 | 12.7478 | 11.7478 |
| Dec 30, 2024 | 12.4578 | 0.9000 | 7.79% | 11.5578 | 12.6778 | 11.4778 |
| Dec 27, 2024 | 11.9378 | 0.6700 | 5.95% | 11.2678 | 12.0378 | 11.0178 |
| Dec 26, 2024 | 11.8878 | 0.8800 | 7.99% | 11.0078 | 11.9078 | 11.0078 |
| Dec 24, 2024 | 11.4078 | 0.6100 | 5.65% | 10.7978 | 11.6978 | 10.7278 |
| Dec 23, 2024 | 11.0778 | -0.4500 | -3.90% | 11.5278 | 11.5278 | 10.0778 |
| Dec 20, 2024 | 11.4178 | -0.5600 | -4.68% | 11.9778 | 12.3278 | 11.2778 |
| Dec 19, 2024 | 12.1478 | 0.6700 | 5.84% | 11.4778 | 12.2178 | 11.1178 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Benitec Biopharma Inc. Company profile
About Benitec Biopharma Inc
Benitec Biopharma Inc is an Australia-based biotechnology company. The Company is focused on developing a therapeutic technology platform that combines ribonucleic acid (RNA) interference with gene therapy for the goal of silencing disease-causing genes from a single administration. The Company's technology, deoxyribonucleic acid (DNA)-directed RNA interference (ddRNAi), is used to develop product candidates in chronic and life-threatening human disease areas including orphan disease and infectious disease. Its pipeline includes BB-301, and BB-103. The Company's lead product candidate, BB-301, is used for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD). Its BB-103 pipeline product is being developed for the treatment of chronic hepatitis B Virus infection.
Financial summary
BRIEF: For the six months ended 31 December 2021, Benitec Biopharma Inc revenues decreased 55% to $25K. Net loss increased 65% to $9.9M. Revenues reflect Licensing revenue segment decrease from $56K to $0K. Higher net loss reflects Research and development - Balancing val increase from $1.9M to $5.8M (expense), Stock-based Compensation in SGA increase from $105K to $349K (expense).
Equity composition
FY'05 is being restated for change in reporting GAAP to IFRS.04/2009, Rights Issue, 1 new share for every 3.142 shares held @ AUD .03 (Factor:1.000000). 04/2011, Rights Issue, 4 new shares for every 5 shares held @ AUD 0.02 (Factor:1.235330). 07/2013, 1-for-25 Reverse Stock split.
| Industry: | Biotechnology & Medical Research (NEC) |
3940 Trust Way
HAYWARD
CALIFORNIA 94545
US
News
TRUMP coin ($TRUMP) price prediction: third-party price target
Read our TRUMP crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:52, 22 January 2025
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
12:40, 31 December 2024
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024People also watch
Still looking for a broker you can trust?
Join the 680,000+ traders worldwide that chose to trade with Capital.com